Skip to Main Content
 

Global Search Box

 
 
 
 

Files

File List


BKP33 Thesis.pdf (8.34 MB)

ETD Abstract Container

Abstract Header

Plant Viral Nanoparticle-based Vaccine Targeting NY-ESO-1+ Triple Negative Breast Cancer

Patel, Bindi, Patel
http://orcid.org/0000-0002-2150-1870
http://rave.ohiolink.edu/etdc/view?acc_num=case1523873757595623

Abstract Details

2018, Master of Sciences, Case Western Reserve University, Biomedical Engineering.
Triple-negative breast cancer (TNBC) is an aggressive, life-threatening disease afflicting 10-20% of all breast cancer patients. The absence of steroid receptors and lack of HER2 receptor overexpression renders standard targeted therapies untenable treatment options limiting postsurgical disease management to systemic chemotherapy. However, the increased likelihood of loco-regional recurrence, metastatic spread and early death (within 5 years of surgical resection) in TNBC patients, underlines an urgent need for identification of new adjuvant therapies to prevent recurrence and prolong disease-free survival. Adjuvant immunotherapies targeted to cancer antigens can prolong disease free survival by recognizing and eliminating residual or recurring disease. NY-ESO-1, a highly immunogenic antigen associated with TNBC and several other malignancies is an appealing target for such interventions. NY-ESO-1 specific cancer vaccines can potentially amplify any pre-existing weak immune response present in NY-ESO-1+ patients and mobilize the immune system to eliminate tumors and metastasis; priming of immune memory by such mechanism holds the potential to prevent recurrence of the disease. Current NY-ESO-1 vaccine strategies are limited by the inherently low immunogenicity and instability of antigenic peptides, use of poorly tolerated adjuvants, ineffective presentation of immunodominant epitopes in recombinant proteins, and costly and technically challenging dendritic cell vaccines. To overcome these shortcomings, I used a highly immunostimulatory and biocompatible viral nanoparticle (VNP) carrier derived from cowpea mosaic virus (CPMV) to stimulate an effective and sustained cytotoxic T cell (CTL) response targeting NY-ESO-1 and test its efficacy in in vitro and ex vivo models.
Nicole Steinmetz (Advisor)
Sourabh Shukla (Committee Chair)
Dominique Durand (Committee Member)
Horst von Recum (Committee Member)
61 p.
Biomedical Engineering
TNBC; immunotherapy; adjuvant; NY-ESO-1; CPMV; CTL

Recommended Citations

Citations

  • Patel, Patel, B. (2018). Plant Viral Nanoparticle-based Vaccine Targeting NY-ESO-1+ Triple Negative Breast Cancer [Master's thesis, Case Western Reserve University]. OhioLINK Electronic Theses and Dissertations Center. http://rave.ohiolink.edu/etdc/view?acc_num=case1523873757595623

    APA Style (7th edition)

  • Patel, Patel, Bindi. Plant Viral Nanoparticle-based Vaccine Targeting NY-ESO-1+ Triple Negative Breast Cancer. 2018. Case Western Reserve University, Master's thesis. OhioLINK Electronic Theses and Dissertations Center, http://rave.ohiolink.edu/etdc/view?acc_num=case1523873757595623.

    MLA Style (8th edition)

  • Patel, Patel, Bindi. "Plant Viral Nanoparticle-based Vaccine Targeting NY-ESO-1+ Triple Negative Breast Cancer." Master's thesis, Case Western Reserve University, 2018. http://rave.ohiolink.edu/etdc/view?acc_num=case1523873757595623

    Chicago Manual of Style (17th edition)

case1523873757595623
250
© 2018, all rights reserved.
This open access ETD is published by Case Western Reserve University School of Graduate Studies and OhioLINK.